C07D 515/20
Spiro-condensed systems
C07D515/20 (Spiro-condensed systems) appears on 17 US grants and 24 published applications in this corpus.
Search patents in C07D- Granted patents
- 17
- Published applications
- 24
- Assignees
- 16
- Inventors
- 182
- Latest grant
- 9 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 2 | 1 |
| 2015 | 1 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 1 | 1 |
| 2021 | 1 | 3 |
| 2022 | 3 | 1 |
| 2023 | 1 | 5 |
| 2024 | 2 | 1 |
| 2025 | 3 | 5 |
| 2026 | 2 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Macrocyclic compounds, compositions, and methods of using thereof9 Jun 2026US 12,649,750 B2Genzyme Corporation
- Macrocyclic compounds, compositions, and methods of using thereof12 May 2026US 12,624,051 B2Genzyme Corporation
- Processes and intermediates for preparing MCL1 inhibitors9 Sep 2025US 12,410,146 B2Gilead Sciences, Inc.
- Spirocyclic inhibitors of hepatitis B virus2 Sep 2025US 12,404,284 B2Istituto Nazionale Genetica Molecolare - Ingm
- Benzotriazole compound5 Aug 2025US 12,378,260 B2Daiichi Sankyo Company, Limited
- Processes and intermediates for preparing mcl1 inhibitors26 Feb 2026US 2026/0055068 A1Gilead Sciences, Inc.
- Macrocyclic compounds, compositions, and methods of using thereof8 Jan 2026US 2026/0008785 A1Genzyme Corporation
- Macrocyclic compounds, compositions, and methods of using thereof8 Jan 2026US 2026/0008786 A1Genzyme Corporation
- Benzotriazole compound23 Oct 2025US 2025/0326770 A1Daiichi Sankyo Company, Limited
- Benzotriazole compound11 Sep 2025US 2025/0282724 A1Daiichi Sankyo Company, Limited
Most cited
By later US patents
- Processes and intermediates for preparing MCL1 inhibitors8US 11,325,891 B2Gilead Sciences, Inc. · 2022
- Spiroimidazolone derivative5US 9,169,254 B2Chugai Seiyaku Kabushiki Kaisha · 2015
- Inhibitors of KEAP1-Nrf2 protein-protein interaction2US 10,947,252 B2Janssen Pharmaceutica NV · 2021
- Compounds that inhibit MCL-1 protein2US 11,306,107 B2Amgen Inc. · 2022
- Processes and intermediates for preparing MCL1 inhibitors2US 11,760,736 B2Gilead Sciences, Inc. · 2023